Loading cancer entity…
Loading cancer entity…
Clinical trials
3,386 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03520985 | Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma(OptiPOM) | terminated | Phase 2 | 34 | Swiss Cancer InstituteOTHER | 1 | Jun 10, 2021 | clinicaltrials |
| NCT00003511 | Antineoplaston Therapy in Treating Patients With Multiple Myeloma | terminated | Phase 2 | 5 | Burzynski Research InstituteOTHER | 1 | Jun 9, 2021 | clinicaltrials |
| NCT02420223 | Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT Recipients | completed | Phase 2 | 25 | Medical College of WisconsinOTHER | 1 | Jun 7, 2021 | clinicaltrials |
| NCT00151203 | Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma | completed | Phase 2 | 50 | Weill Medical College of Cornell UniversityOTHER | 1 | May 27, 2021 | clinicaltrials |
| NCT00538733 | Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma(T-BiRD) | completed | Phase 2 | 26 | Weill Medical College of Cornell UniversityOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT03670173 | Safety and Efficacy Assessments of Osalmid in Multiple Myeloma | unknown | Phase 1 / Phase 2 | 20 | Shanghai 10th People's HospitalOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT04891744 | Selinexor in Combination With Thalidomide and Dexamethasone in RRMM | unknown | Phase 1 / Phase 2 | 48 | Li ZhengOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT03910439 | Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | May 12, 2021 | clinicaltrials |
| NCT01018979 | Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients | completed | Phase 2 | 19 | GPCR Therapeutics, Inc.INDUSTRY | 1 | May 11, 2021 | clinicaltrials |
| NCT03606577 | An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients(IFM 2018-04) | active not recruiting | Phase 2 | 50 | Nantes University HospitalOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT03795597 | Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)(BuMelCarAuto) | unknown | Phase 1 / Phase 2 | 36 | Loyola UniversityOTHER | 1 | Apr 26, 2021 | clinicaltrials |
| NCT01177735 | Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma | completed | Phase 2 | 71 | University of ArkansasOTHER | 1 | Apr 22, 2021 | clinicaltrials |
| NCT01458288 | A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease | completed | Phase 2 | 12 | GPCR Therapeutics, Inc.INDUSTRY | 1 | Apr 19, 2021 | clinicaltrials |
| NCT02104427 | PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients | completed | Phase 2 | 12 | GPCR Therapeutics, Inc.INDUSTRY | 1 | Apr 19, 2021 | clinicaltrials |
| NCT01045460 | Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma(aMILs) | completed | Phase 2 | 36 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 9, 2021 | clinicaltrials |
| NCT04439214 | Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Apr 6, 2021 | clinicaltrials |
| NCT00773838 | Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095) | completed | Phase 2 | 143 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 1, 2021 | clinicaltrials |
| NCT03340883 | Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM) | terminated | Phase 1 / Phase 2 | 21 | Chinook Therapeutics, Inc.INDUSTRY | 1 | Apr 1, 2021 | clinicaltrials |
| NCT03262389 | Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma | completed | Phase 2 | 10 | Michael C Roarke, MDOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT01402284 | Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Mar 2, 2021 | clinicaltrials |
| NCT02078102 | A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma | completed | Phase 2 | 38 | Sherif S. FaragOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT04762745 | The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 56 | Sun Yat-sen UniversityOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT00437034 | Aflibercept for Relapsed Multiple Myeloma | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2021 | clinicaltrials |
| NCT00489203 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 140 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT01380106 | Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma | completed | Phase 2 | 33 | Boston VA Research Institute, Inc.OTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT03512353 | A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers | terminated | Phase 2 | 7 | AmgenINDUSTRY | 1 | Jan 8, 2021 | clinicaltrials |
| NCT00621244 | A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies | completed | Phase 1 / Phase 2 | 175 | Novartis PharmaceuticalsINDUSTRY | 3 | Jan 5, 2021 | clinicaltrials |
| NCT01930162 | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant(UCBT) | completed | Phase 2 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 5, 2021 | clinicaltrials |
| NCT01058434 | Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation | completed | Phase 2 | 43 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 19, 2020 | clinicaltrials |
| NCT00708292 | A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma. | completed | Phase 1 / Phase 2 | 29 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 17, 2020 | clinicaltrials |
| NCT01302886 | Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma | completed | Phase 2 | 41 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 17, 2020 | clinicaltrials |
| NCT01337752 | Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency | completed | Phase 2 | 9 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 17, 2020 | clinicaltrials |
| NCT01121120 | Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients(TXA127-PBSC) | terminated | Phase 2 | 75 | Tarix PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT01045681 | Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma(BVD) | completed | Phase 2 | 75 | Intergroupe Francophone du MyelomeNETWORK | 1 | Dec 7, 2020 | clinicaltrials |
| NCT01426828 | Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant | completed | Phase 2 | 40 | University of PennsylvaniaOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT03117361 | Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide | terminated | Phase 2 | 10 | PharmaMarINDUSTRY | 3 | Dec 2, 2020 | clinicaltrials |
| NCT01155583 | Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 45 | Case Comprehensive Cancer CenterOTHER | 1 | Nov 16, 2020 | clinicaltrials |
| NCT02897830 | Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma(IFM2014-03) | terminated | Phase 2 | 46 | University Hospital, ToulouseOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT03033316 | A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in Patients With Progressive Multiple Myeloma(AMETHYST) | terminated | Phase 1 / Phase 2 | 7 | Enceladus Pharmaceuticals BVINDUSTRY | 0 | Nov 6, 2020 | clinicaltrials |
| NCT00966693 | Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 77 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT03287804 | APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma(APRIL) | terminated | Phase 1 / Phase 2 | 12 | Autolus LimitedINDUSTRY | 2 | Oct 23, 2020 | clinicaltrials |
| NCT02477215 | Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 38 | Parameswaran HariOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT02217163 | Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple Myeloma | completed | Phase 2 | 30 | Singapore General HospitalOTHER | 1 | Oct 20, 2020 | clinicaltrials |
| NCT00821249 | A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 55 | PfizerINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02092922 | A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM) | completed | Phase 2 | 154 | PfizerINDUSTRY | 8 | Oct 19, 2020 | clinicaltrials |
| NCT02192775 | UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus | completed | Phase 2 | 2 | University of ArkansasOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02237261 | Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma(BPV) | completed | Phase 2 | 46 | University Hospital HeidelbergOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02991898 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | terminated | Phase 2 | 3 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 29, 2020 | clinicaltrials |
| NCT00469209 | Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients | completed | Phase 1 / Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Jun 10, 2021source: clinicaltrials